Basic Pharma: Local recombinant rHSA, animal-free

Based in Geleen, Basic Pharma is a full-service (bio)pharmaceutical partner supporting biotech companies, pharma and academia across development, manufacturing and lifecycle management. Alongside its pharmaceutical activities, the company operates a biotech division specialising in recombinant protein production using microbial platforms (yeast and bacteria).

This makes Basic Pharma a strong, locally anchored partner for organisations aiming to shorten their supply chain while maintaining flexible scale‑up options. The approach aligns with the European Unions’ Pharmaceutical Strategy (2020), which promotes resilient, sustainable and locally anchored supply chains for medicines and critical raw materials.

Recombinant HSA: consistent, safe and locally produced

A key product in the portfolio is recombinant human serum albumin (rHSA), expressed in the yeast Hansenula polymorpha. This production approach ensures the protein is fully animal-free and removes risks associated with plasma-derived materials, such as viral contamination or supply variability.

For labs and manufacturers, this translates into:

• High batch-to-batch, consistency for reproducible results
• Animal-free origin, supporting regulatory and ethical requirements
• Secure local supply chain, reducing lead times and import dependencies

Each batch is tested and delivered with a Certificate of Analysis (CoA), ensuring full transparency and quality assurance.

From research to scale-up

Basic Pharma supports both non-GMP and future GMP-compatible projects, allowing users to start in R&D and seamlessly scale their processes. This makes it an attractive partner for organisations seeking long-term continuity in their supply chain.

Available via Bio‑Connect

Through Bio Connect, customers gain direct access to Basic Pharma’s recombinant protein portfolio, including rHSA as well as proteins such as histones, sfGFP and proteases. In parallel, Basic Pharma offers custom services covering strain development, upstream and downstream processing (USP/DSP), analytical- and R&D-support.

With this combined expertise, Basic Pharma supports the development and manufacturing of recombinant proteins for a wide range of uses, including culture media supplements and use in areas such as R&D, diagnostics, pharma and agro/food.

For labs that want to move towards animal‑free, recombinant and locally produced solutions, the Basic Pharma – Bio‑Connect collaboration is a solid choice within the “Local & Sustainable Sourcing” theme.

Interested in evaluating rHSA or discussing your application? Contact Bio Connect for technical support, quotes or samples.